GL1X · GenesisL1 explorer

Research workbench

Mycobacterium tuberculosis cytochrome P450 CYP121 in complex with lead compound 21

Analyse Mycobacterium tuberculosis cytochrome P450 CYP121 in complex with lead compound… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7NQO
Type
protein
Length
394 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Mycocyclosin synthase
EC
1.14.19.70
UniProt
P9WPP7
Ligands
HEC, ULZ, SO4, CL
Pockets
2 · best druggability 0.87

Structure

x-ray diffraction · 1 distinct chain · 52% helix, 10% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMycocyclosin synthase (EC 1.14.19.70)protein39452% helix, 10% strandP9WPP7

Ligands and binding sites

  • HEC · Heme C · ligand · chains A
  • ULZ · 4-[4-[2-(5-bromanyl-1~{H}-indol-3-yl)ethyl]pyrimidin-2-yl]morpholine · ligand · chains A
  • SO4 · Sulfate ion · ion · 9 copies · chains A
  • CL · Chloride ion · ion · 2 copies · chains A
  • MES · 2-(N-morpholino)-ethanesulfonic acid · additive · 2 copies · chains A
  • DMS · Dimethyl sulfoxide · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18300.870.8974HEC, ULZ
2580.280.7415empty

Compared structures

  • 7NQO · Mycobacterium tuberculosis Cytochrome P450 CYP121 in complex with lead compound 21 · the same entry in another collection · chain A against A, TM-score 1.00
  • P9WPP7 · AlphaFold monomer V2.0 prediction for mycocyclosin synthase (P9WPP7) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.